Российский биотерапевтический журнал

Расширенный поиск

Патологические изменения дендритных клеток при раке

Полный текст:

Об авторах

Антон Артурович Кескинов
ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» Минздрава России; Университет г. Питтсбург

М. Р. Щурин
Университет г. Питтсбург

В. М. Бухман
ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» Минздрава России

З. С. Шпрах
ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» Минздрава России

Список литературы

1. Sato K., Fujita S. Dendritic cells: nature and classification. Allergol Int 2007;56(3):183-91. DOI: 10.2332/ allergolint.R-06-139. PMID: 17646733.

2. Wollenberg A., Mommaas M., Oppel T. et al. Expression and function of the mannose receptor CD206 on epidermal dendritic cells in inflammatory skin diseases. J Invest Dermatol 2002;118(2):327-34. DOI: 10.1046/j.0022-202x.2001.01665.x. PMID: 11841552.

3. Guttman-Yassky E., Lowes M.A., Fuentes-Duculan J. et al. Major differences in inflammatory dendritic cells and their products distinguish atopic dermatitis from psoriasis. J Allergy Clin Immun 2007;119(5):1210-7. DOI: 10.1016/j.jaci.2007.03.006.

4. Segura E., Touzot M., Bohineust A. et al. Human Inflammatory Dendritic Cells Induce Th17 Cell Differentiation. Immunity 2013;38(2):336-48. DOI: 10.1016/j.immuni.2012.10.018.

5. Lutz M.B., Schuler G. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunol 2002;23(9):445-9. DOI: S1471490602022810[pii]. PMID: 12200066.

6. Menges M., Rossner S., Voigtlander C. et al. Repetitive injections of dendritic cells matured with tumor necrosis factor alpha induce antigen-specific protection of mice from autoimmunity. J Exper Med 2002;195(1):15-21. PMID: 11781361.

7. Shurin G.V., Ma Y., Shurin M.R. Immunosuppressive mechanisms of regulatory dendritic cells in cancer. Cancer microenviron 2013;6(2):159-67. DOI: 10.1007/s12307-013-0133-3. PMID: 23749739; PMCID: PMC3717058.

8. Manavalan J.S., Rossi P.C., Vlad G. et al. High expression of ILT3 and ILT4 is a general feature of tolerogenic dendritic cells. Transpl Immunol 2003;11(3-4): 245-58. DOI: 10.1016/s0966-3274(03)00058-3. PMID: 12967778.

9. Anderson A.E., Sayers B.L., Haniffa M.A. et al. Differential regulation of naive and memory CD4+ T cells by alternatively activated dendritic cells. J Leukoc Biol 2008;84(1):124-33. DOI: 10.1189/ jlb.1107744. PMID: 18430785; PMCID: Pmc2504714.

10. Dai H., Zhu H., Lei P. et al. Programmed death-1 signaling is essential for the skin allograft protection by alternatively activated dendritic cell infusion in mice. Transplantation 2009;88(7): 864-73. DOI: 10.1097/ TP.0b013e3181b6ea74. PMID: 19935456.

11. Papenfuss T.L., Powell N.D., McClain M.A. et al. Estriol generates tolerogenic dendritic cells in vivo that protect against autoimmunity. J Immunol 2011;186(6): 3346-55. DOI: 10.4049/jimmunol.1001322. PMID: 21317386; PMCID: Pmc3600583.

12. Scott C.L., Aumeunier A.M., Mowat A.M. Intestinal CD103+ dendritic cells: master regulators of tolerance? Trends Immunol 2011;32(9):412-9. DOI: 10.1016/ PMID: 21816673.

13. Ma Y., Shurin GV., Gutkin D.W., Shurin M.R. Tumor associated regulatory dendritic cells. Semin cancer biol 2012;22(4):298-306. DOI: 10.1016/j.semcancer.2012.02.010. PMID: 22414911; PMCID: PMC3373995.

14. Qian C., Cao X. Naturally occurring CD1c+ human regulatory dendritic cells: immunoregulators that are expanded in response to E. coli infection. Eur J Immunol 2012;42(6):1388-92. DOI: 10.1002/eji.201242632. PMID: 22678895.

15. Liu Q., Zhang C., Sun A. et al. Tumor-educated CD11bhighIalow regulatory dendritic cells suppress T cell response through arginase I. J Immunol 2009;182(10):6207-16. PMID: 19414774.

16. Shurin G.V., Ouellette C.E., Shurin M.R. Regulatory dendritic cells in the tumor immunoenvironment. Cancer Immunol Immunother 2012;61(2):223-30. PMID: 22065047.

17. Shurin M.R. Dendritic cells presenting tumor antigen. Cancer Immunol Immunother 1996;43(3):158-64. PMID: 9001569.

18. Schuler G., Steinman R.M. Dendritic cells as adjuvants for immune-mediated resistance to tumors. J Exp Med 1997;186(8):1183-7. PMID: 9379142.

19. Esche C., Shurin M.R., Lotze M.T. The use of dendritic cells for cancer vaccination. Curr Opin Mol Ther 1999;1(1):72-81. PMID: 11249687.

20. Mukherji B., Chakraborty N.G., Yamasaki S. et al. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. PNAS 1995;92(17): 8078-82. PMID: 7644541.

21. Hsu F.J., Benike C., Fagnoni F. et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996;2(1):52-8. PMID: 8564842.

22. Murphy G., Tjoa B., Ragde H. et al. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 1996;29(6):371-80. PMID: 8977634.

23. Engleman E.G. Dendritic cells in the treatment of cancer. Biol Blood Marrow Transplant 1996;2(3):115-7. PMID: 9199753.

24. Engleman E.G. Dendritic cells: potential role in cancer therapy. Cytotechnology 1997;25(1-3):1-8. PMID: 9474803.

25. Zhong H., Han B., Tourkova I.L. et al. Low-dose paclitaxel prior to intratumoral dendritic cell vaccine modulates intratumoral cytokine network and lung cancer growth. Clin Cancer Res 2007; 13(18 Pt 1):5455-62. PMID: 17875775.

26. Anguille S., Smits E.L., Lion E. et al. Clinical use of dendritic cells for cancer therapy. Lancet Oncol 2014;15(7):e257-67. DOI: 10.1016/s1470-2045(13)70585-0. PMID: 24872109.

27. Ma Y., Shurin G.V., Peiyuan Z., Shurin M.R. Dendritic cells in the cancer microenvironment. Journal of Cancer 2013;4(1):36-44. DOI: 10.7150/jca.5046. PMID: 23386903; PMCID: Pmc3564245.

28. Fridman W.-H., Dieu-Nosjean M.-C., Pagès F. et al. The Immune Microenvironment of Human Tumors: General Significance and Clinical Impact. Cancer Microenvironment 2013;6(2):117-22. DOI: 10.1007/s12307-012-0124-9. PMID: PMC3717061.

29. Stene M.A., Babajanians M., Bhuta S., Cochran A.J. Quantitative alterations in cutaneous Langerhans cells during the evolution of malignant melanoma of the skin. J Invest Dermatol 1988;91(2):125-8. PMID: 3260930.

30. Alcalay J., Goldberg L.H., Wolf J.E.Jr., Kripke M.L. Variations in the number and morphology of Langerhans' cells in the epidermal component of squamous cell carcinomas. Arch Dermatol 1989;125(7):917-20. PMID: 2742388.

31. Lissoni P., Vigore L., Ferranti R. et al. Circulating dendritic cells in early and advanced cancer patients: diminished percent in the metastatic disease. JBRHA 1999;13(4):216-9. PMID: 10703945.

32. Ratta M., Fagnoni F., Curti A. et al. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood 2002;100(1):230-7. PMID: 12070032.

33. Tabarkiewicz J., Rybojad P., Jablonka A., Rolinski J. CD1c+ and CD303+ dendritic cells in peripheral blood, lymph nodes and tumor tissue of patients with non-small cell lung cancer. Ocol Rep 2008;19(1):237-43. PMID: 18097601.

34. Chevolet I., Speeckaert R., Schreuer M. et al. Clinical significance of plasmacytoid dendritic cells and myeloid-derived suppressor cells in melanoma. J Transl Med 2015;13:9. DOI: 10.1186/s12967-014-0376-x. PMID: 25592374; PMCID: Pmc4326397.

35. Shurin M.R. Regulation of dendropoiesis in cancer. Clin Immunol Newsletter 1999;19(10/11):135-9.

36. Shurin G.V., Shurin M.R., Bykovskaia S. et al. Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function. Cancer Res 2001;61(1):363-9. PMID: 11196188.

37. Shurin G.V., Aalamian M., Pirtskhalaishvili G. et al. Human prostate cancer blocks the generation of dendritic cells from CD34+ hematopoietic progenitors. Eur Urol 2001;39(Suppl 4): 37-40. PMID: 11340288.

38. Rughetti A., Pellicciotta I., Biffoni M. et al. Recombinant tumor-associated MUC1 glycoprotein impairs the differentiation and function of dendritic cells. J Immunol 2005;174(12):7764-72. PMID: 15944279.

39. Ogden A.T., Horgan D., Waziri A. et al. Defective receptor expression and dendritic cell differentiation of monocytes in glioblastomas. Neurosurgery 2006;59(4):902-9; discussion 9-10. DOI: 10.1227/01.neu.0000233907.03070.7b. PMID: 17038955.

40. Hasebe H., Nagayama H., Sato K. et al. Dysfunctional regulation of the development of monocyte-derived dendritic cells in cancer patients. Biomed Pharmacother 2000;54(6):291-8. DOI: 10.1016/s0753-3322(00)80050-5. PMID: 10989961.

41. O'Toole A., Michielsen A.J., Nolan B. et al. Tumour microenvironment of both early- and late-stage colorectal cancer is equally immunosuppressive. Br J Cancer 2014;111(5):927-32. DOI: 10.1038/ bjc.2014.367. PMID: 25058349.

42. Gabrilovich D.I., Chen H.L., Girgis K.R. et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996;2(10):1096-103. PMID: 8837607.

43. Chomarat P., Banchereau J., Davoust J., Palucka A.K. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat Immunol 2000;1(6):510-4. DOI: 10.1038/82763. PMID: 11101873.

44. Lin M.F., Mou H.B., Cen H. [Effects of transforming growth factor beta1 on dendritic cells function]. Zhonghua xue ye xue za zhi 2004;25(8):449-52. PMID: 15555257.

45. O'Donnell R.K., Mick R., Feldman M. et al. Distribution of dendritic cell subtypes in primary oral squamous cell carcinoma is inconsistent with a functional response. Cancer Lett 2007;255(1):145-52. DOI: 10.1016/j.canlet.2007.04.003. PMID: 17574329; PMCID: PMC2121220.

46. Takagi S., Miyagawa S., Ichikawa E. et al. Dendritic cells, T-cell infiltration, and Grp94 expression in cholangiocellular carcinoma. Hum Pathol 2004;35(7):881-6. PMID: 15257553.

47. Furihata M., Ono Y., Ichikawa K. et al. Prognostic significance of CD83 positive, mature dendritic cells in the gallbladder carcinoma. Oncol Rep 2005;14(2):353-6. PMID: 16012714.

48. Aso T., Ogawa Y., Naoe M. et al. Immunohistochemical analysis of CD83, CD8 and CD4 positive cells in renal cell carcinoma. Nippon Hinyokika Gakkai Zasshi 2004;95(4):645-50. PMID: 15197997.

49. Esche C., Lokshin A., Shurin G.V. et al. Tumor's other immune targets: dendritic cells. J Leukoc Biol 1999;66(2):336-44. PMID: 10449178.

50. Katsenelson N.S., Shurin G.V., Bykovskaia S.N. et al. Human small cell lung carcinoma and carcinoid tumor regulate dendritic cell maturation and function. Mod Pathol 2001;14(1):40-5. PMID: 11211308.

51. Kiertscher S.M., Luo J., Dubinett S.M., Roth M.D. Tumors promote altered maturation and early apoptosis of monocyte-derived dendritic cells. J Immunol 2000;164(3):1269-76.

52. Onishi H., Morisaki T., Baba E. et al. Dysfunctional and short-lived subsets in monocyte-derived dendritic cells from patients with advanced cancer. Clin Immunol 2002;105(3):286-95. PMID: 12498810.

53. Onishi H., Morisaki T., Kuroki H. et al. Evaluation of a dysfunctional and shortlived subset of monocyte-derived dendritic cells from cancer patients. Anticancer Res 2005;25(5):3445-51. PMID: 16101162.

54. Pinzon-Charry A., Maxwell T., McGuckin M.A. et al. Spontaneous apoptosis of blood dendritic cells in patients with breast cancer. Breast Cancer Res 2006;8(1):R5. PMID: 16417648.

55. Esche C., Shurin G.V., Kirkwood J.M. et al. Tumor necrosis factor-alpha-promoted expression of Bcl-2 and inhibition of mitochondrial cytochrome c release mediate resistance of mature dendritic cells to melanoma-induced apoptosis. Clin Cancer Res 2001;7(3 Suppl):974s-9s.

56. Balkir L., Tourkova I.L., Makarenkova V.P. et al. Comparative analysis of dendritic cells transduced with different anti-apoptotic molecules: sensitivity to tumor-induced apoptosis. J Gene Med 2004;6(5):537-44. DOI: 10.1002/jgm.545. PMID: 15133764.

57. Esche C., Gambotto A., Satoh Y. et al. CD154 inhibits tumor-induced apoptosis in dendritic cells and tumor growth. Eur J Immunol 1999;29(7):2148-55. DOI: 10.1002/(sici)1521-4141(199907) 29:07<2148::aid-immu2148>;2-f. PMID: 10427977.

58. Yang T., Witham T.F., Villa L. et al. Glioma-associated hyaluronan induces apoptosis in dendritic cells via inducible nitric oxide synthase: implications for the use of dendritic cells for therapy of gliomas. Cancer Res 2002;62(9):2583-91. PMID: 11980653.

59. Peguet-Navarro J., Sportouch M., Popa I. et al. Gangliosides from human melanoma tumors impair dendritic cell differentiation from monocytes and induce their apoptosis. J Immunol 2003;170(7):3488-94. PMID: 12646609.

60. Ishida A., Ohta M, Toda M. et al. Mucin-induced apoptosis of monocyte-derived dendritic cells during maturation. Proteomics 2008;8(16):3342-9. DOI: 10.1002/pmic.200800039. PMID: 18690650.

61. Kusume A., Sasahira T., Luo Y. et al. Suppression of dendritic cells by HMGB1 is associated with lymph node metastasis of human colon cancer. Pathobiology 2009;76(4):155-62. DOI: 10.1159/000218331. PMID: 19571604.

62. Alcalay J., Kripke M.L. Antigen-presenting activity of draining lymph node cells from mice painted with a contact allergen during ultraviolet carcinogenesis. J Immunol 1991;146(6):1717-21. PMID: 1672330.

63. Halliday G.M., Reeve V.E., Barnetson R.S. Langerhans cell migration into ultraviolet light-induced squamous skin tumors is unrelated to anti-tumor immunity. J Invest Dermatol 1991;97(5):830-4. PMID: 1680931.

64. Halliday G.M., Lucas A.D., Barnetson R.S. Control of Langerhans' cell density by a skin tumour-derived cytokine. Immunology 1992;77(1):13-8. PMID: 1398759.

65. Becker Y. Dendritic cell activity against primary tumors: an overview. In Vivo 1993;7(3):187-91. PMID: 8357960.

66. Tas M.P., Simons P.J., Balm F.J., Drexhage H.A. Depressed monocyte polarization and clustering of dendritic cells in patients with head and neck cancer: in vitro restoration of this immunosuppression by thymic hormones. Cancer Immunol Immunother 1993;36(2):108-14.

67. Stoger H., Wilders-Truschnig M., Samonigg H. et al. The presence of immunosuppressive 'p15E-like' factors in the serum and urine of patients suffering from malign and benign breast tumours. Clin Exp Immunol 1993;93(3):437-41. PMID: 8370172.

68. Aalamian M., Pirtskhalaishvili G., Nunez A. et al. Human prostate cancer regulates generation and maturation of monocyte-derived dendritic cells. Prostate 2001;46(1):68-75. PMID: 11170134.

69. Chaux P., Moutet M., Faivre J. et al. Inflammatory cells infiltrating human colorectal carcinomas express HLA class II but not B7-1 and B7-2 costimulatory molecules of the T-cell activation. Lab Invest 1996;74(5):975-83. PMID: 8642792.

70. Satthaporn S., Robins A., Vassanasiri W. et al. Dendritic cells are dysfunctional in patients with operable breast cancer. Cancer Immunol Immunother 2004;53(6):510-8. PMID: 14740176.

71. Kichler-Lakomy C., Budinsky A.C., Wolfram R. et al. Deficiences in phenotype expression and function of dentritic cells from patients with early breast cancer. Eur J Med Res 2006;11(1):7-12. PMID: 16504954.

72. Gabrilovich D.I., Ciernik I.F., Carbone D.P. Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts. Cell Immunol 1996;170(1):101-10. PMID: 8665590.

73. Ni X.Y., Sui H.X., Liu Y. et al. TGF-beta of lung cancer microenvironment upregulates B7H1 and GITRL expression in dendritic cells and is associated with regulatory T cell generation. Oncology reports 2012;28(2):615-21. DOI: 10.3892/ or.2012.1822. PMID: 22614805.

74. Krempski J., Karyampudi L., Behrens M.D. et al. Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer. J Immunol 2011;186(12):6905-13. PMID: 21551365.

75. Nestle F.O., Burg G., Fah J. et al. Human sunlight-induced basal-cell-carcinoma-associated dendritic cells are deficient in T cell co-stimulatory molecules and are impaired as antigen-presenting cells. Am J Pathol 1997;150(2):641-51. PMID: 9033277; PMCID: Pmc1858265.

76. Brown R.D., Pope B., Murray A. et al. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10. Blood 2001;98(10):2992-8. PMID: 11698282.

77. Enk A.H., Jonuleit H., Saloga J., Knop J. Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. Int J Cancer 1997;73(3):309-16. DOI: 10.1002/(SICI)1097-0215(19971104) 73:3<309::AID-IJC1>3.0.CO;2-3[pii]. PMID: 9359474.

78. Pedroza-Gonzalez A., Zhou G., Vargas-Mendez E. et al. Tumor-infiltrating plasmacytoid dendritic cells promote immunosuppression by Tr1 cells in human liver tumors. Oncoimmunology 2015;4(6):e1008355. DOI: 10.1080/2162402 x.2015.1008355. PMID: 26155417; PMCID: Pmc4485712.

79. Ghirelli C., Reyal F., Jeanmougin M. et al. Breast Cancer Cell-Derived GM-CSF Licenses Regulatory Th2 Induction by Plasmacytoid Predendritic Cells in Aggressive Disease Subtypes. Cancer Res 2015;75(14):2775-87. DOI: 10.1158/0008-5472.can-14-2386. PMID: 25977333.

80. Aspord C., Leccia M.T., Charles J., Plumas J. Plasmacytoid dendritic cells support melanoma progression by promoting Th2 and regulatory immunity through OX40L and ICOSL. Cancer Immunol Res 2013;1(6):402-15. DOI: 10.1158/2326-6066.cir-13-0114-t. PMID: 24778133.

81. Demoulin S., Herfs M., Delvenne P., Hubert P. Tumor microenvironment converts plasmacytoid dendritic cells into immunosuppressive/tolerogenic cells: insight into the molecular mechanisms. J Leukoc Biol 2013;93(3):343-52. DOI: 10.1189/jlb.0812397. PMID: 23136258.

82. Gai X.D., Song Y., Li C. et al. Potential role of plasmacytoid dendritic cells for FOXP3+ regulatory T cell development in human colorectal cancer and tumor draining lymph node. Pathol Res Pract 2013;209(12):774-8. DOI: 10.1016/j. prp.2013.08.011. PMID: 24080284.

83. Conrad C., Gregorio J., Wang Y.H. et al. Plasmacytoid dendritic cells promote immunosuppression in ovarian cancer via ICOS costimulation of Foxp3(+) T-regulatory cells. Cancer Res 2012;72(20):5240-9. DOI: 10.1158/0008-5472.can-12-2271. PMID: 22850422; PMCID: Pmc3652570.

84. Huang X.M., Liu X.S., Lin X.K. et al. Role of plasmacytoid dendritic cells and inducible costimulator-positive regulatory T cells in the immunosuppression microenvironment of gastric cancer. Cancer Science 2014;105(2):150-8. DOI: 10.1111/cas.12327. PMID: 24261990; PMCID: Pmc4317822.

85. Sisirak V., Faget J., Vey N. et al. Plasmacytoid dendritic cells deficient in IFNalpha production promote the amplification of FOXP3+ regulatory T cells and are associated with poor prognosis in breast cancer patients. Oncoimmunology 2013;2(1):e22338. DOI: 10.4161/ onci.22338. PMID: 23482834; PMCID: Pmc3583914.

86. Ramos R.N., de Moraes C.J., Zelante B, Barbuto J.A. What are the molecules involved in regulatory T-cells induction by dendritic cells in cancer? Clinical & developmental immunology 2013;2013:806025. DOI: 10.1155/2013/806025. PMID: 23762097; PMCID: Pmc3674660.

87. Ghiringhelli F., Puig P.E., Roux S. et al. Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med 2005;202(7):919-29. DOI: jem.20050463 [pii]10.1084/ jem.20050463. PMID: 16186184.

88. Aspord C., Pedroza-Gonzalez A., Gallegos M. et al. Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development. J Exp Med 2007;204(5):1037-47. DOI: 10.1084/ jem.20061120. PMID: 17438063; PMCID: PMC2118566.

89. Popov A., Abdullah Z., Wickenhauser C. et al. Indoleamine 2,3-dioxygenaseexpressing dendritic cells form suppurative granulomas following Listeria monocytogenes infection. The Journal of clinical investigation 2006;116(12):3160-70. DOI: 10.1172/JCI28996. PMID: 17111046.

90. Saint-Mezard P., Chavagnac C., Bosset S. et al. Psychological stress exerts an adjuvant effect on skin dendritic cell functions in vivo. J Immunol 2003;171(8):4073-80. PMID: 14530328.

91. Seiffert K., Granstein R.D. Neuroendocrine regulation of skin dendritic cells. Ann N Y Acad Sci 2006;1088:195- 206. DOI: 10.1196/annals.1366.011. PMID: 17192566.

92. Makarenkova V.P., Esche C., Kost N.V. et al. Identification of delta- and mu-type opioid receptors on human and murine dendritic cells. J Neuroimmunol 2001;117(1 -2):68-77. PMID: 11431006.

93. Piemonti L., Monti P., Allavena P. et al. Glucocorticoids affect human dendritic cell differentiation and maturation. J Immunol 1999;162(11):6473-81. PMID: 10352262.

94. Maestroni G.J. Dendritic cell migration controlled by alpha 1b-adrenergic receptors. J Immunol 2000;165(12):6743-7. PMID: 11120793.

95. Bellik L., Gerlini G., Parenti A. et al. Role of conventional treatments on circulating and monocyte-derived dendritic cells in colorectal cancer. Clin Immunol 2006;121(1):74-80. PMID: 16914380.

96. Shurin M.R., Naiditch H., Gutkin D.W. et al. ChemoImmunoModulation: immune regulation by the antineoplastic chemotherapeutic agents. Curr Med Chem 2012;19(12):1792-803. PMID: 22414087.

97. Kaneno R., Shurin G.V., Kaneno F.M. et al. Chemotherapeutic agents in low noncytotoxic concentrations increase immunogenicity of human colon cancer cells. Cell Oncol (Dordr) 2011;34(2):97- 106. PMID: 21290210.

98. Shurin M.R., Shurin G.V., Chatta G.S. Aging and the dendritic cell system: implications for cancer. Crit Rev Oncol Hematol 2007;64(2):90-105.

99. Tkach A.V., Shurin G.V., Shurin M.R. et al. Direct effects of carbon nanotubes on dendritic cells induce immune suppression upon pulmonary exposure. ACS nano 2011;5(7):5755-62. PMID: 21657201.

100. Tkach A.V., Yanamala N., Stanley S. et al. Graphene oxide, but not fullerenes, targets immunoproteasomes and suppresses antigen presentation by dendritic cells. Small 2013;9(9-10):1686-90. DOI: 10.1002/smll.201201546. PMID: 22887961.


Для цитирования:

Кескинов А.А., Щурин М.Р., Бухман В.М., Шпрах З.С. Патологические изменения дендритных клеток при раке. Российский биотерапевтический журнал. 2016;15(4):25-33.

For citation:

Keskinov A.A., Shurin M.R., Bukhman V.M., Shprakh Z.S. PATHOPHYSIOLOGY OF DENDRITIC CELLS IN CANCER. Russian Journal of Biotherapy. 2016;15(4):25-33. (In Russ.)

Просмотров: 540

Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.

ISSN 1726-9784 (Print)
ISSN 1726-9792 (Online)